Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2023-02-07 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
第九届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company regarding a specific decision about waiving a share acquisition right. It includes details about the meeting, attendance, and voting results. There is no indication of financial statements, audit results, or detailed financial data. It is not a full report like an Annual Report or Interim Report. It is also not a regulatory certification or a general regulatory filing. The document is an official announcement of a board/management decision, specifically from the Supervisory Board, which falls under Board/Management Information (MANG).
2023-02-07 Chinese
独立董事关于公司放弃在第二个窗口期对福建和瑞被收购方实施股权收购权的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the company's decision to waive a right to acquire shares in a related party during a specified window period. It references compliance with company law, stock exchange listing rules, and internal governance documents. The content focuses on board-level approval and disclosure obligations related to a specific transaction, indicating it is related to board or management information about corporate governance and decision-making. The document is short (529 characters) and does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. It is not a full audit report, annual report, or earnings release. It is best classified as Board/Management Information (MANG) because it concerns board approval and independent directors' opinions on a corporate transaction.
2023-02-07 Chinese
第九届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of the company, including decisions on waiving a share acquisition right and scheduling a shareholders' meeting. It details the meeting date, attendance, voting results, and procedural compliance. There is no financial data, earnings information, or detailed report content. The document is not a full report but an announcement of board decisions and upcoming shareholder meeting arrangements. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2023-02-07 Chinese
2022年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2022年度业绩预告' which translates to '2022 Annual Performance Forecast'. It provides an earnings forecast for the fiscal year 2022, including expected net profit/loss figures and explanations for the performance changes. It explicitly states that the data is preliminary, unaudited, and that the final audited results will be in the 2022 Annual Report. The document is short (1388 characters) and serves as an earnings guidance or forecast rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures and outlook. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. Therefore, the correct classification is Earnings Release (ER). FY 2022
2023-01-30 Chinese
关于全资子公司取得欧洲专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (874 characters) about the company's wholly owned subsidiary obtaining a European patent certificate. It includes details about the patent and its significance to the company. There is no financial data, no mention of a report or filing, and it is clearly an announcement of a patent grant. It does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not related to management changes, voting results, or capital changes. The document is a regulatory announcement about intellectual property, which does not fit into any specific category but is best classified as a Regulatory Filing (RNS) under the fallback category for miscellaneous filings that do not fit elsewhere.
2023-01-12 Chinese
北京市金杜律师事务所关于成都市贝瑞和康基因技术股份有限公司2023年第一次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2023 first extraordinary general meeting (临时股东大会) of Chengdu Berry Genomics Co., Ltd. It details the legal compliance of the meeting's call, attendance, and voting results. The document does not contain financial statements or management discussion but focuses on the legality and procedural correctness of the shareholders' meeting. It is not an announcement of voting results per se, but a legal opinion on the meeting's conduct. Given the nature of the document as a legal opinion related to a shareholders' meeting, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length is about 5150 characters, and it is not a brief announcement or a report publication notice. Therefore, the classification is RNS with high confidence.
2023-01-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.